Clinical trial NCT02915354 - References

Recurrence — Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Following-up Study

Citation(s)

•   Baji P, Péntek M, Szántó S, Géher P, Gulácsi L, Balogh O, Brodszky V
  Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. Eur J Health Econ. 2014 May;15 Suppl 1:S45-52. doi: 10.1007/s10198-014-0593-5. Review.
•   Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Rudwaleit M, Sieper J, Braun J
  Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther. 2005;7(3):R439-44. Erratum in: Arthritis Res Ther. 2005;7(3):113. Zink, Angela [added];Alten, Rieke [added]; Burmester, Gerd [added]; Gromnica-Ihle, Erika [added]; Kellner, Herbert [added]; Schneider, Matthias [added]; Sörensen, Helmut [added]; Zeidler, Henning [added]; Rudwaleit, Martin [added].
•   Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, Gromnica-Ihle E, Haibel H, Schewe S, Schneider M, Sörensen H, Zeidler H, Visvanathan S, Sieper J, Braun J
  Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol. 2007 Mar;34(3):510-5.
•   Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J
  Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford). 2005 Mar;44(3):342-8. Erratum in: Rheumatology (Oxford). 2005 Apr;44(4):569.
•   Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E
  New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr Opin Rheumatol. 2001 Jul;13(4):245-9. Review.
•   Braun J, Sieper J
  The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol. 1996 Jul;8(4):275-87. Review.
•   de Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M
  Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol. 2000 Dec;27(12):2860-5.
•   Gorman JD, Sack KE, Davis JC Jr
  Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002 May 2;346(18):1349-56.
•   Kiltz U, Baraliakos X, Braun J, van der Heijde D
  Withdrawal of medical therapies in axial spondyloarthritis: what would be the optimal trial design? Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78):S47-50.
•   Li ZH, Zhang Y, Wang J, Shi ZJ
  Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. Eur J Orthop Surg Traumatol. 2013 Jul;23(5):497-506. doi: 10.1007/s00590-012-1035-7. Review.
•   Lin Q, Lin Z, Gu J, Huang F, Li T, Wei Q, Liao Z, Cao S, Jiang Y, Huang J
  Abnormal high-expression of CD154 on T lymphocytes of ankylosing spondylitis patients is down-regulated by etanercept treatment. Rheumatol Int. 2010 Jan;30(3):317-23. doi: 10.1007/s00296-009-0958-8.

Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Three Years' Following-up Study

Details for clinical trial NCT02915354